Investigation Overview
An investigation on behalf of current long-term investors in shares of Eidos Therapeutics, Inc. (NASDAQ: EIDX) was announced over potential breaches of fiduciary duties by certain officers and directors at Eidos Therapeutics, Inc. The investigation by a law firm concerns whether certain Eidos Therapeutics directors breached their fiduciary duties and caused damage to the company and ...
You must register (for free) or login to view the entire investigation.